- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03884283
Prospective, Multi-center Study to Assess Posterolateral Fusion Using FIBERGRAFT
April 18, 2024 updated by: Prosidyan, Inc.
A Post-market, Prospective, Multi-center, Nonrandomized Study to Assess Posterolateral Lumbar Fusions Using FIBERGRAFT BG Matrix
This is a prospective, non-randomized (single arm), multi-center, post-market clinical study designed to evaluate FIBERGRAFT® BG Matrix mixed with autograft and bone marrow aspirate in up to 150 subjects with degenerative disc disease (DDD) with or without radiculopathy, or spinal stenosis and/or spondylolisthesis requiring a fusion.
The patient population will include adult (skeletally mature) men and women undergoing 1 or 2 level fusion in the lumbar spine (L2-S1) who are deemed eligible for the study, characterized by inclusion and exclusion criteria.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Long Beach, California, United States, 90806
- Memorial Orthopaedic Surgical Group
-
Long Beach, California, United States, 90806
- Long Beach Medical Center
-
-
Florida
-
Wellington, Florida, United States, 33449
- Palm Beach Neurosurgery
-
-
Kentucky
-
Paducah, Kentucky, United States, 42001
- Orthopaedic Institute of Western Kentucky
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Washington Spine & Scoliosis Institute at OrthoBethesda
-
-
New York
-
Great Neck, New York, United States, 11021
- Northwell Health Orthopaedic Institute
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- KeiperSpine, PC
-
-
Texas
-
Fort Worth, Texas, United States, 76132
- Orthopedic and Neurologic Research Institute
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia Orthopaedics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Signed Informed Consent Form
- Is at least 18 years of age and skeletally mature.
- Must have symptomatic spinal stenosis and/or spondylolisthesis or degenerative disc disease (DDD) at one or two adjacent levels from L2-S1, requiring a fusion.
- Must have completed a minimum of three months of unsuccessful conservative, non-operative care.
- DDD and spinal stenosis and/or spondylolisthesis must be confirmed by MRI or CT scans.
- Must score at least 40 points on the Oswestry Disability Index.
- Must score at least a 4 on a 10 cm Visual Analog Scale for back or leg pain.
- Must be able to comply with the protocol's follow-up schedule.
- Must understand and sign the IRB approved informed consent document.
Exclusion Criteria:
- Symptomatic at more than two levels.
- Previous fusion surgery at any lumbar level with or without instrumentation (prior discectomy, laminotomy, laminectomy or nucleolysis at the index level (> 6 months) is permitted).
- Previous total disc replacement at any lumbar level.
- Undergoing fusion for recurrent stenosis at the level to be treated.
- Extraspinal cause of back and/or leg pain, or back and/or leg pain of unknown etiology.
- Spondylolisthesis not able to be reduced to grade I.
- Lumbar scoliosis greater than 11 degrees.
- Osteoporosis*, osteopenia, osteomalacia, Paget's disease, or metabolic or systemic bone disorders that affect bone or wound healing.
- Use of posterior instrumentation for stabilization is not possible.
- Intra-operative soft tissue coverage is not possible.
- Spinal tumors.
- Active arachnoiditis.
- Fractures of the epiphyseal plate or fractures for which stabilization of the fracture is not possible.
- Impaired calcium metabolism.
- Active systemic infection or surgical site infection.
- Osteomyelitis at the graft site.
- Rheumatoid arthritis or other autoimmune disease.
- Chronic steroid use (used steroids for one month within the last 6 months) or any medical condition that requires treatment with drugs known to interfere with bone healing.
- Systemic disease such as AIDS, HIV, hepatitis (active), tuberculosis.
- Morbid obesity defined as body mass index (BMI) >40 or a weight more than 100 lbs over ideal body weight.
- Smokers unless the subject agrees to quit at least 2 weeks prior to and for the duration of the study, confirmed by a carboxyhemoglobin test prior to surgery.
- Psychosocial disorders that would preclude accurate evaluation or has a history of recent substance abuse.
- Active malignancy except non-melanoma skin cancer; history of any invasive malignancy unless treated and in remission for at least five years.
- Documented allergies to titanium.
- Subjects with a history of anaphylaxis, history of multiple allergies, known allergies to bovine collagen, or who are being treated for desensitization to meat products because FIBERGRAFT® BG Matrix contains bovine collagen.
- Pregnancy/able to become pregnant and not following a reliable contraceptive method, or interested in becoming pregnant in the next two years.
- Participation in another investigational study within 30 days.
- Prisoners.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spinal fusion
Time Frame: 12 months
|
Spinal fusion will be determined via radiographic imaging at 12 months.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 19, 2019
Primary Completion (Actual)
May 21, 2023
Study Completion (Actual)
May 21, 2023
Study Registration Dates
First Submitted
March 19, 2019
First Submitted That Met QC Criteria
March 19, 2019
First Posted (Actual)
March 21, 2019
Study Record Updates
Last Update Posted (Actual)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 18, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom
Clinical Trials on FIBERGRAFT BG Matrix
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2United States
-
University of ZagrebRecruitingPain, Postoperative | Gingival Recession, Localized | Hyaluronic AcidCroatia
-
Ascensia Diabetes CareCompleted
-
Ascensia Diabetes CareCompletedDiabetesUnited States
-
Ascensia Diabetes CareCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
Ascensia Diabetes CareCompleted
-
Pakistan Institute of Medical SciencesRecruiting
-
Ascensia Diabetes CareCompleted